| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this study was to elucidate the role of DC-SIGN, whose involvement in anti-inflammatory action of intravenous immunoglobulin was reported, in structure and function of therapeutic antibodies. SNA-lectin absorbed fraction purified from intravenous immunoglobulin or recombinant IgG prepared by co-transfection of the plasmids encoding IgG and sialyl transferase were used as sialylated IgG. Binding assay using DC-SIGN expressing cells and Surface plasmon resonance spectroscopy were performed. However, binding between sialylated IgG and DC-SIGN was not observed. Other mechanism than direct binding between DC-SIGN and sialylated IgG may be involved in the anti-inflammatory action of therapeutic IVIG.
|
